Shuichi Suetani blogs a new study published today in The Lancet Psychiatry, which suggests that those patients who might benefit most from evidence-based guidance are the least represented in clinical trials about ADHD medication. Is it time to reconsider the value we place on RCTs when they do not include the vast majority of people who need help?
[read the full story...]